Thank you for sharing!

Your article was successfully shared with the contacts you provided.
A subsidiary of medical device manufacturer Guidant Corp. is ending production of an aortic abdominal graft, only days after the unit pleaded guilty to criminal charges for covering up problems involving the product that may have led to 12 deaths. Endovascular Technologies Inc., a subsidiary of Indianapolis-based Guidant, pleaded guilty to 10 felonies last week involving its Ancure “stent-graft” device, including shipping misbranded products and making false statements to government regulators. Endovascular faces $92.4 million in federal penalties for actions surrounding the device. Guidant officials said Monday that Menlo Park, Calif.-based Endovascular would continue to ship the device and provide support to patients until October. The company then will cease ongoing operations other than continuing to provide long-term services for patients who have received the device. Ronald Dollens, Guidant’s president and chief executive, said the company regrets the reporting errors by Endovascular, which Guidant bought in 1997. “Guidant has learned a painful lesson about integrating acquired businesses,” Dollens said. “People who should have known better acted improperly and displayed poor judgment. Once that improper conduct was recognized, Guidant properly overhauled the business.” Guidant officials said they expected the total after-tax loss from the discontinued operations, including settlement charges and operating losses, to be $100 million to $125 million for 2003. The majority of affected employees will be offered other positions within Guidant, the company said. In afternoon trading on the New York Stock Exchange Monday, Guidant shares were up 15 cents to $40.10. “Guidant’s financial outlook remains strong,” Dollens said. “Potential liability from civil litigation is manageable. Our relationship with the FDA is sound, the corporation is enjoying healthy growth.” The problems with the device, used during operations to treat abdominal aortic aneurysms, were resolved after the device was voluntarily recalled in March 2001 and before it was reintroduced five months later, the company said. The device, inserted through the groin, was designed to let doctors patch the aneurysm without requiring risky surgery to open the abdomen. The criminal complaint against Endovascular alleged the company misled federal regulators and reported only 172 malfunctions. Prosecutors said Endovascular had records of 2,628 malfunctions, including reports that the incidents may have led to 12 deaths and 57 surgeries to remove the device. Guidant faces a class action shareholders lawsuit filed last week after its subsidiary pleaded guilty to criminal charges. Guidant has more than 10,000 employees and makes instruments to treat heart and vascular disease including pacemakers, defibrillators and drug-coated stents. Copyright 2003 Associated Press. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed.

Want to continue reading?
Become a Free ALM Digital Reader.

Benefits of a Digital Membership:

  • Free access to 3 articles* every 30 days
  • Access to the entire ALM network of websites
  • Unlimited access to the ALM suite of newsletters
  • Build custom alerts on any search topic of your choosing
  • Search by a wide range of topics

*May exclude premium content
Already have an account?


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.